Gene expression profiling of primary cultures of ovarian epithelial cells identifies novel molecular classifiers of ovarian cancer

British Journal of Cancer

Volumn 94, Issue 3, 2006, Pages 436-445

  Le Page, C ^a   Quellet, V ^a   Madore, J ^a   Ren, F ^a   Hudson, T J ^c,d   Tonin, P N ^c,d   Provencher, D M ^a,b   Mes Masson, A M ^a,b  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

BMP 2; Mesothelin; Microarray; Molecular marker; Ovarian cancer

Indexed keywords

BIOLOGICAL MARKER; BONE MORPHOGENETIC PROTEIN 2; MESOTHELIN; TUMOR MARKER;

ARTICLE; ASCITES; CANCER CELL; CELL CULTURE; CONTROLLED STUDY; DNA MICROARRAY; EPITHELIUM CELL; FEMALE; GENE CLUSTER; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NUCLEOTIDE SEQUENCE; OVARY CANCER; OVARY CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOLID TUMOR; STATISTICAL ANALYSIS; TUMOR CELL; VALIDATION PROCESS;

BONE MORPHOGENETIC PROTEINS; CELLS, CULTURED; EPITHELIAL CELLS; FEMALE; GENE EXPRESSION PROFILING; GENES, NEOPLASM; HUMANS; MEMBRANE GLYCOPROTEINS; NA(+)-K(+)-EXCHANGING ATPASE; NEOPLASM STAGING; OVARIAN NEOPLASMS; OVARY; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 32544440192     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602933     Document Type: Article

References (43)

1. Adib TR, Henderson S, Perrett C, Hewitt D, Bourmpoulia D, Ledermann J, Boshoff C (2004) Predicting biomarkers for ovarian cancer using gene-expression microarrays. Br J Cancer 90: 686-692
2. Amid C, Bahr A, Mujica A, Sampson N, Bikar SE, Winterpacht A, Zabel B, Hankeln T, Schmidt ER (2001) Comparative genomic sequencing reveals a strikingly similar architecture of a conserved syntenic region on human chromosome 11p15.3 (including gene ST5) and mouse chromosome 7. Cytogenet Cell Genet 93: 284-290
3. Beer DG, Kardia SL, Huang CC, Giordano TJ, Levin AM, Misek DE, Lin L, Chen G, Gharib TG, Thomas DG, Lizyness ML, Kuick R, Hayasaka S, Taylor JM, Iannettoni MD, Orringer MB, Hanash S (2002) Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 8: 816-824
4. Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, Karlan BY (2003) Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 97: 2187-2195
5. Chang XH, Cheng YX, Zhang XY, Cui H, Feng J (2003) [Monitoring novel ovarian carcinoma associated genes using cDNA expression microarray]. Zhonghua Fu Chan Ke Za Zhi 38: 322-324
6. Donninger H, Bonome T, Radonovich M, Pise-Masison CA, Brady J, Shih JH, Barrett JC, Birrer MJ (2004) Whole genome expression profiling of advance stage papillary serous ovarian cancer reveals activated pathways. Oncogene 23: 8065-8077
7. Drapkin R, Crum CP, Hecht JL (2004) Expression of candidate tumor markers in ovarian carcinoma and benign ovary: evidence for a link between epithelial phenotype and neoplasia. Hum Pathol 35: 1014-1021
8. Dyrskjot L, Thykjaer T, Kruhoffer M, Jensen JL, Marcussen N, Hamilton-Dutoit S, Wolf H, Orntoft TF (2003) Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet 33: 90-96
9. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE (1994) Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 343: 692-695
10. Gilks CB, Vanderhyden BC, Zhu S, van de Rijn M, Longacre TA (2005) Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling. Gynecol Oncol 96: 684-694
11. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller H, Loh ML, Downing JR, Caligiuri MA, Bloomfield CD, Lander ES (1999) Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286: 531-537
12. Gordon GJ, Richards WG, Sugarbaker DJ, Jaklitsch MT, Bueno R (2003) A prognostic test for adenocarcinoma of the lung from gene expression profiling data. Cancer Epidemiol Biomarkers Prev 12: 905-910
13. Hibbs K, Skubitz KM, Pambuccian SE, Casey RC, Burleson KM, Oegema TR, Jr, Thiele JJ, Grindle SM, Bliss RL, Skubitz AP (2004) Differential gene expression in ovarian carcinoma: identification of potential biomarkers. Am J Pathol 165: 397-414
14. Kruk PA, Maines-Bandiera SL, Auersperg N (1990) A simplified method to culture human ovarian surface epithelium. Lab Invest 63: 132-136
15. Lancaster JM, Dressman HK, Whitaker RS, Havrilesky L, Gray J, Marks JR, Nevins JR, Berchuck A (2004) Gene expression patterns that characterize advanced stage serous ovarian cancers. J Soc Gynecol Investig 11: 51-59
16. Le Page C, Provencher D, Maugard CM, Quellet V, Mes-Masson AM (2004) Signature of a silent killer: expression profiling in epithelial ovarian cancer. Expert Rev Mol Diagn 4: 157-167
17. Lee BC, Cha K, Avraham S, Avraham HK (2004) Microarray analysis of differentially expressed genes associated with human ovarian cancer. Int J Oncol 24: 847-851
18. Lichy JH, Modi WS, Seuanez HN, Howley PM (1992) Identification of a human chromosome 11 gene which is differentially regulated in tumorigenic and nontumorigenic somatic cell hybrids of HeLa cells. Cell Growth Differ 3: 541-548
19. Lounis H, Provencher D, Godbout C, Fink D, Milot MJ, Mes-Masson AM (1994) Primary cultures of normal and tumoral human ovarian epithelium: a powerful tool for basic molecular studies. Exp Cell Res 215: 303-309
20. Lu KH, Patterson AP, Wang L, Marquez RT, Atkinson EN, Baggerly KA, Ramoth LR, Rosen DG, Liu J, Hellstrom I, Smith D, Hartmann L, Fishman D, Berchuck A, Schmandt R, Whitaker R, Gershenson DM, Mills GB, Bast Jr RC (2004) Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res 10: 3291-3300
21. Marks JR, Davidoff AM, Kerns BJ, Humphrey PA, Pence JC, Dodge RK, Clarke-Pearson DL, Iglehart JD, Bast Jr RC, Berchuck A (1991) Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res 51: 2979-2984
22. McIntosh MW, Drescher C, Karlan B, Scholler N, Urban N, Hellstrom KE, Hellstrom I (2004) Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. Gynecol Oncol 95: 9-15
23. Meinhold-Heerlein I, Bauerschlag D, Hilpert F, Dimitrov P, Sapinoso LM, Orlowska-Volk M, Bauknecht T, Park TW, Jonat W, Jacobsen A, Sehouli J, Luttges J, Krajewski M, Krajewski S, Reed JC, Arnold N, Hampton GM (2005) Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. Oncogene 24: 1053-1065
24. Meltzer PS, Jankowski SA, Dal Cin P, Sandberg AA, Paz IB, Coccia MA (1991) Identification and cloning of a novel amplified DNA sequence in human malignant fibrous histiocytoma derived from a region of chromosome 12 frequently rearranged in soft tissue tumors. Cell Growth Differ 2: 495-501
25. Neibergs HL, Hein DW, Spratt JS (2002) Genetic profiling of colon cancer. J Surg Oncol 80: 204-213
26. Okamoto A, Sameshima Y, Yokoyama S, Terashima Y, Sugimura T, Terada M, Yokota J (1991) Frequent allelic losses and mutations of the p53 gene in human ovarian cancer. Cancer Res 51: 5171-5176
27. Ordonez NG (2003) Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol 27: 1418-1428
28. Ouellet V, Provencher DM, Maugard CM, Le Page C, Ren F, Lussier C, Novak J, Ge B, Hudson TJ, Tonin PN, Mes-Masson AM (2005) Discrimination between serous low malignant potential and invasive epithelial ovarian tumors using molecular profiling. Oncogene 24: 4672-4687
29. Palazzo JP, Monzon F, Burke M, Hyslop T, Dunton C, Barusevicius A, Capuzzi D, Kovatich AJ (2000) Overexpression of p21WAF1/CIP1 and MDM2 characterizes serous borderline ovarian tumors. Hum Pathol 31: 698-704
30. Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45
31. Ramaswamy S, Tamayo P, Rifkin R, Mukherjee S, Yeang CH, Angelo M, Ladd C, Reich M, Latulippe E, Mesirov JP, Poggio T, Gerald W, Loda M, Lander ES, Golub TR (2001) Multiclass cancer diagnosis using tumor gene expression signatures. Proc Natl Acad Sci USA 98: 15149-15154
32. Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, Spellman P, Iyer V, Jeffrey SS, Van de Rijn M, Waltham M, Pergamenschikov A, Lee JC, Lashkari D, Shalon D, Myers TG, Weinstein JN, Botstein D, Brown PO (2000) Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 24: 227-235
33. Santin AD, Zhan F, Bellone S, Palmieri M, Cane S, Bignotti E, Anfossi S, Gokden M, Dunn D, Roman JJ, O'Brien TJ, Tian E, Cannon MJ, Shaughnessy Jr J, Pecorelli S (2004) Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy. Int J Cancer 112: 14-25
34. Schaner ME, Ross DT, Ciaravino G, Sorlie T, Troyanskaya O, Diehn M, Wang YC, Duran GE, Sikic TL, Caldeira S, Skomedal H, Tu IP, Hernandez-Boussard T, Johnson SW, O'Dwyer PJ, Fero MJ, Kristensen GB, Borresen-Dale AL, Hastie T, Tibshirani R, van de Rijn M, Teng NN, Longacre TA, Botstein D, Brown PO, Sikic BI (2003) Gene expression patterns in ovarian carcinomas. Mol Biol Cell 14: 4376-4386
35. Schwartz DR, Kardia SL, Shedden KA, Kuick R, Michailidis G, Taylor JM, Misek DE, Wu R, Zhai Y, Darrah DM, Reed H, Ellenson LH, Giordano TJ, Fearon ER, Hanash SM, Cho KR (2002) Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res 62: 4722-4729
36. Shipp MA, Ross KN, Tamayo P, Weng AP, Kutok JL, Aguiar RC, Gaasenbeek M, Angelo M, Reich M, Pinkus GS, Ray TS, Koval MA, Last KW, Norton A, Lister TA, Mesirov J, Neuberg DS, Lander ES, Aster JC, Golub TR (2002) Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 8: 68-74
37. Simon R (2003) Using DNA microarrays for diagnostic and prognostic prediction. Expert Rev Mol Diagn 3: 587-595
38. Tamayo P, Slonim D, Mesirov J, Zhu Q, Kitareewan S, Dmitrovsky E, Lander ES, Golub TR (1999) Interpreting patterns of gene expression with self-organizing maps: methods and application to hematopoietic differentiation. Proc Natl Acad Sci USA 96: 2907-2912
39. Tusher VG, Tibshirani R, Chu G (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 98: 5116-5121
40. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-536
41. Warrenfeltz S, Pavlik S, Datta S, Kraemer ET, Benigno B, McDonald JF (2004) Gene expression profiling of epithelial ovarian tumours correlated with malignant potential. Mol Cancer 3: 27
42. Welsh JB, Zarrinkar PP, Sapinoso LM, Kern SG, Behling CA, Monk BJ, Lockhart DJ, Burger RA, Hampton GM (2001) Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci USA 98: 1176-1181
43. Zhang X, Feng J, Cheng Y, Yao Y, Ye X, Fu T, Cheng H (2005) Characterization of differentially expressed genes in ovarian cancer by cDNA microarrays. Int J Gynecol Cancer 15: 50-57